Medi Caps

Why is Medi Caps Ltd falling/rising?

As of 28-Jun, Medi Caps Ltd's stock price is declining at 27.27, down 2.47%, and has underperformed its sector and the Sensex significantly over various time periods. The stock has seen a year-to-date decline of 12.68% and a 35.59% drop over the past year, with reduced investor interest reflected in a 43.3% decrease in delivery volume.

As of 28-Jun, Medi Caps Ltd's stock price is falling, currently at 27.27, which reflects a change of -0.69 or -2.47%. The stock has underperformed its sector by 2.19% today and has shown a negative trend over various time periods. Over the past week, the stock has decreased by 1.12%, while it has experienced a more significant decline of 12.68% year-to-date and 35.59% over the past year. <BR><BR>Additionally, the stock's performance relative to the benchmark Sensex indicates a concerning trend, as it has underperformed significantly over the last three years, with a decline of 26.67% compared to the Sensex's gain of 22.42%. The moving averages suggest that the stock is currently lower than the 5-day, 20-day, 50-day, and 200-day averages, although it is higher than the 100-day moving average. <BR><BR>Investor participation has also decreased, with delivery volume falling by 43.3% against the 5-day average, indicating reduced interest in the stock. Overall, these factors contribute to the current decline in Medi Caps Ltd's stock price.

Which are the latest news on Medi Caps?

How big is Medi Caps?

As of 10th June, Medi Caps Ltd has a market capitalization of 36.00 Cr, with Net Sales of 12.46 Cr and a Net Profit loss of 3.04 Cr over the latest four quarters. Shareholder's Funds are 121.28 Cr and Total Assets are 125.42 Cr as of March 2025.

As of 10th June, Medi Caps Ltd has a market capitalization of 36.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Medi Caps reported Net Sales of 12.46 Cr. However, the company experienced a loss of 3.04 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 121.28 Cr and Total Assets were reported at 125.42 Cr.

Who are in the management team of Medi Caps?

The management team of Medi Caps includes R C Mittal (Chairman), Alok K Garg (Managing Director), and several non-executive and independent directors, such as Pramod Fatehpuria and Ashok Omprakash Agrawal, along with Company Secretary Abhishek Kumar. They are responsible for overseeing the company's operations and governance.

The management team of Medi Caps includes the following individuals:<BR><BR>1. R C Mittal - Chairman (Non-Executive)<BR>2. Alok K Garg - Managing Director<BR>3. Pramod Fatehpuria - Non-Executive & Independent Director<BR>4. Ashok Omprakash Agrawal - Non-Executive & Independent Director<BR>5. Kusum Mittal - Non-Executive Director<BR>6. Dharmendra Solanki - Independent Director<BR>7. Abhishek Kumar - Company Secretary & Compliance Officer<BR>8. Gajendra Singh - Independent Director<BR><BR>This team plays a crucial role in overseeing the company's operations and governance.

Who are the peers of the Medi Caps?

Medi Caps' peers include Sandu Pharma, Murae Organisor, Lasa Supergeneri, Roopa Industries, ANG Lifesciences, Chandra Bhagat, Welcure Drugs, Guj. Terce Labs, and Shree Ganesh Bio. Most peers exhibit below average management risk and growth, with Chandra Bhagat showing the highest 1-year return at -24.31% and Murae Organisor the lowest at -83.76%.

Peers: Medi Caps has the following peers: Sandu Pharma., Murae Organisor, Lasa Supergeneri, Roopa Industries, ANG Lifesciences, Chandra Bhagat, Welcure Drugs, Guj. Terce Labs., and Shree Ganesh Bio.<BR><BR>Quality Snapshot: Below Average management risk is observed at Sandu Pharma., Murae Organisor, Lasa Supergeneri, Roopa Industries, ANG Lifesciences, Chandra Bhagat, Guj. Terce Labs., and Shree Ganesh Bio, while Average management risk is found at Welcure Drugs. Growth is Excellent at Roopa Industries, Good at Murae Organisor, and Average at Welcure Drugs, while Below Average growth is noted for Sandu Pharma., Lasa Supergeneri, ANG Lifesciences, Chandra Bhagat, Guj. Terce Labs., and Shree Ganesh Bio. Capital Structure is Good at Sandu Pharma., Medi Caps, Welcure Drugs, and Shree Ganesh Bio, while Below Average is seen at Murae Organisor, Lasa Supergeneri, ANG Lifesciences, Chandra Bhagat, and Guj. Terce Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Chandra Bhagat at -24.31%, while Murae Organisor has the lowest at -83.76%. Medi Caps' 1-year return of -37.73% is better than Murae Organisor's but worse than Chandra Bhagat's. Additionally, the six-month return is negative for Welcure Drugs, Murae Organisor, Lasa Supergeneri, Roopa Industries, ANG Lifesciences, and Guj. Terce Labs.

What does Medi Caps do?

Medi Caps Ltd is a micro-cap pharmaceutical company that manufactures empty hard gelatine capsules for dosaged medicines, with a market cap of INR 36 Cr and recent net sales and profit of 3 Cr each for March 2026. The company was established in 1983 and became public in 1986.

Overview: <BR>Medi Caps Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacture of empty hard gelatine capsules for dosaged medicines.<BR><BR>History: <BR>Medi Caps Limited was incorporated in August 1983 as a Private Limited Company and converted into a Public Limited Company in March 1986. The latest quarterly results reported net sales and net profit of 3 Cr for March 2026.<BR><BR>Financial Snapshot: <BR>- Net Sales: 3 Cr (Quarterly Results - Mar 2026) <BR>- Net Profit: 3 Cr (Quarterly Results - Mar 2026) <BR>- Market cap: INR 36 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: N/A <BR>- Industry P/E: 34 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.21 <BR>- Return on Equity: -2.72% <BR>- Price to Book: 0.30 <BR><BR>Contact Details: <BR>Address: Mhow-Neemuch Road, Sector - I Pithampur Madhya Pradesh : 454775 <BR>Tel: 91-07292-424242 <BR>Email: investors@medicaps.com <BR>Website: http://www.medicaps.com

Are Medi Caps Ltd latest results good or bad?

Medi Caps Ltd's latest results are concerning, showing a net profit of ₹3.04 crores mainly due to one-time income, while revenues plummeted by 50.50% year-on-year and operating margins are deeply negative at -60.23%. Overall, the company's fundamentals indicate significant operational challenges and a distressed state, warranting caution for investors.

Medi Caps Ltd's latest results present a mixed picture that leans towards the negative. While the company reported a net profit of ₹3.04 crores for Q4 FY26, which is a significant increase of 76.74% year-on-year, this profit is largely misleading. It was primarily driven by exceptional other income of ₹5.59 crores, which accounted for 184.49% of profit before tax. Without this one-time income, the company would have faced substantial operational losses of ₹2.06 crores.<BR><BR>On the revenue front, Medi Caps experienced a severe decline, with revenues falling to ₹3.45 crores, marking a 50.50% year-on-year decrease and a 19.77% drop from the previous quarter. This decline indicates significant challenges in the company's core operations and market position.<BR><BR>Additionally, the operating margin is deeply negative at -60.23%, reflecting an unsustainable business model. The company's return on equity (ROE) is also alarmingly low at 1.46%, with a recent quarterly ROE of -4.84%, suggesting that it is actively destroying shareholder value.<BR><BR>Overall, while the reported profit figure may seem positive at first glance, the underlying operational performance is concerning, with significant revenue contraction and unsustainable margins. This situation raises serious questions about the company's future viability and operational health. Investors should approach Medi Caps with caution, as the fundamentals indicate a distressed state rather than a recovery.

Should I buy, sell or hold Medi Caps Ltd?

When is the next results date for Medi Caps Ltd?

The next results date for Medi Caps Ltd is 21 May 2026.

The next results date for Medi Caps Ltd is scheduled for 21 May 2026.

How has been the historical performance of Medi Caps?

Medi Caps has experienced a significant decline in net sales and profitability, with net sales dropping from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25, resulting in operating losses and negative profits over the same period. The company's total assets also decreased slightly, reflecting ongoing financial challenges.

Answer:<BR>The historical performance of Medi Caps shows a significant decline in net sales and profitability over the years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Medi Caps experienced a downward trend in net sales, dropping from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25. This decline is mirrored in total operating income, which also fell from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25. The company's total expenditure, excluding depreciation, decreased from 59.92 Cr in Mar'22 to 27.30 Cr in Mar'25, yet this was not sufficient to prevent operating losses, with operating profit (PBDIT) declining from 11.86 Cr in Mar'22 to -1.83 Cr in Mar'25. Profit before tax also turned negative, moving from 10.06 Cr in Mar'22 to -0.84 Cr in Mar'25, and profit after tax followed suit, decreasing from 10.04 Cr in Mar'22 to -0.57 Cr in Mar'25. The company's cash flow from operating activities showed a slight decrease from 7.00 Cr in Mar'22 to 5.00 Cr in Mar'25, while total assets slightly decreased from 130.35 Cr in Mar'22 to 125.42 Cr in Mar'25. Overall, Medi Caps has faced significant challenges, reflected in its declining sales, profitability, and asset values over the past few years.

Is Medi Caps overvalued or undervalued?

As of February 9, 2024, Medi Caps is considered undervalued with a low Price to Book Value of 0.44 and a negative PE Ratio of -53.55, despite its recent stock performance showing a YTD return of -10.77%, indicating a significant shift from a very expensive to a risky valuation grade compared to peers like Sun Pharma and Divi's Lab.

As of 9 February 2024, Medi Caps has moved from a valuation grade of very expensive to risky, indicating a significant shift in its financial outlook. The company is currently assessed as undervalued, primarily due to its low Price to Book Value of 0.44 and a negative PE Ratio of -53.55. Other notable ratios include an EV to EBITDA of -13.35 and a ROCE of -3.85%, which further highlight the company's struggles.<BR><BR>When compared to its peers, Medi Caps stands out with a PEG Ratio of 0.00, while competitors like Sun Pharma and Divi's Lab have significantly higher PE Ratios of 35.25 and 79.33, respectively. This stark contrast suggests that Medi Caps may be undervalued relative to its peers, despite its current financial challenges. Additionally, the company's recent stock performance shows a YTD return of -10.77%, underperforming against the Sensex, which returned 5.62% in the same period.

What is the technical trend for Medi Caps?

As of June 4, 2025, Medi Caps shows a mildly bearish technical trend, with mixed signals from the MACD and bearish indicators from moving averages and Bollinger Bands.

As of 4 June 2025, the technical trend for Medi Caps has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are bearish in both weekly and monthly time frames, and daily moving averages are also bearish. The KST shows a mildly bullish stance on the weekly chart but is mildly bearish on the monthly. There are no clear trends indicated by Dow Theory in either time frame. Overall, the current technical stance is mildly bearish, driven primarily by the bearish signals from moving averages and Bollinger Bands, despite some mildly bullish indicators in the MACD and KST on the weekly chart.

Who are the top shareholders of the Medi Caps?

The top shareholders of Medi Caps include Alok K Garg, who holds 25.87%, and individual investors with a combined 44.57%. The highest public shareholder is Sangeetha S at 5.57%, with no pledged promoter holdings and minimal mutual fund or foreign institutional investor involvement.

The top shareholders of Medi Caps include the promoters, with Alok K Garg holding the highest stake at 25.87%. Individual investors collectively hold 44.57% of the shares, while the highest public shareholder is Sangeetha S, who owns 5.57%. Additionally, there are no pledged promoter holdings, and the company has minimal mutual fund and foreign institutional investor involvement.

What is the bonus history of the Medi Caps?

Medi Caps issued a 3:1 bonus in 2013, where shareholders received three additional shares for each share held. The ex-date was March 19, 2013, and the record date was March 20, 2013.

Medi Caps has a bonus history that includes a significant bonus issue announced in 2013. Specifically, the company issued a 3:1 bonus, which means that for every one share held, shareholders received three additional shares. The ex-date for this bonus was March 19, 2013, and the record date was March 20, 2013. This was the latest recorded bonus action for the company.

Has Medi Caps declared dividend?

Medi Caps Ltd has declared a 15% dividend, amounting to 0.3800 per share, but the dividend yield is 0% as no recent dividends have been paid out. Total returns have varied significantly, with a 333.3% increase over the past 5 years despite negative returns in shorter periods.

Medi Caps Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 0.3800<BR>- Ex-date: 20 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -17.38%, the dividend return was 0%, resulting in a total return of -17.38%.<BR><BR>In the 1-year period, the price return was -5.29%, the dividend return was 0%, resulting in a total return of -5.29%.<BR><BR>In the 2-year period, the price return was 18.03%, the dividend return was 0%, resulting in a total return of 18.03%.<BR><BR>In the 3-year period, the price return was -13.68%, the dividend return was 0%, resulting in a total return of -13.68%.<BR><BR>In the 4-year period, the price return was -7.57%, the dividend return was 0%, resulting in a total return of -7.57%.<BR><BR>In the 5-year period, the price return was 333.3%, the dividend return was 0%, resulting in a total return of 333.3%.<BR><BR>Overall, while Medi Caps has declared a dividend, the dividend yield remains at 0%, indicating no recent dividends have been paid out. The total returns show significant volatility, with a notable increase over the 5-year period despite negative returns in shorter time frames.